论文部分内容阅读
眼肌型重症肌无力引起上睑下垂和(或)复视等临床症状,影响患者的日常生活和工作。它被认为是一种轻型的疾病,但临床上约有一半的眼肌型患者肌电图表现为全身神经肌肉功能紊乱,且44%~53%的眼肌型患者有可能进展为全身型的重症肌无力。有资料证实应用免疫抑制疗法减少了眼肌型患者进展成全身型的频率。在权衡免疫抑制疗法的利弊后可根据患者的情况制定个体化的治疗方案。
Ocular muscular myasthenia gravis caused by ptosis and (or) diplopia and other clinical symptoms affect the daily lives of patients and work. It is considered a mild disease, but about half of the EMG patients with ocular muscle showed systemic neuromuscular dysfunction, and 44% to 53% of oculomotor patients may progress to the systemic Myasthenia gravis There is data to confirm the application of immunosuppressive therapy to reduce the ocular muscle type of patients progress into the body type frequency. After weighing the pros and cons of immunosuppressive therapy according to the patient’s situation to develop individualized treatment options.